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A B S T R A C T
Background: Rhododendrol (RD), a skin-whitening agent, is believed to be associated with cases of
cosmetics-related leukoderma that have been reported in Japan. Recently, we have shown that RD is
catalyzed by tyrosinase to produce putative toxic metabolites RD-catechol and RD-cyclic catechol.
Objective: To examine the cytotoxicity and production of reactive oxygen species (ROS) in melanocytic
cells by RD and its metabolic products.
Methods: The growth inhibitory effect of RD or its metabolite on the normal human epidermal
melanocyte (NHEM) and B16F1 cells was assessed by cell counting or WST assay. ROS production was
detected by ﬂow cytometry and confocal microscopy after cells were treated with 20,70-dichloro-
ﬂuorescein and RD or its metabolite.
Results: Growth of NHEM derived from African American (NHEMb) and B16F1 cells was suppressed by
300 mM or more RD. Growth inhibitory activity of RD (IC50 of B16F1: 671 mM) was weaker than
hydroquinone (IC50 of B16F1: 28.3 mM) or resveratrol (IC50 of B16F1: 27.1 mM). Flow cytometric
analysis detected ROS production in the NHEMb and B16F1 cells exposed to RD. However, neither RD nor
H2O2 increased the subG1 fraction of these melanocytic cells. RD-catechol and RD-cyclic catechol
inhibited growth of NHEMb and B16F1 cells muchmore strongly than did RD. RD-catechol, as well as RD,
produced ROS detected by both ﬂow cytometry and immunostaining, while RD-cyclic catechol produced
a hardly detectable amount of ROS in B16F1 cells.
Conclusions: These results suggest that RD exerts the cytotoxicity in melanocytic cells through its
oxidative metabolites and that ROS plays a role in RD-mediated cytotoxicity.
 2015 The Authors. Published by Elsevier Ireland Ltd. on behalf of Japanese Society for Investigative
n access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Melanin pigment is produced in the melanocytes and trans-
ferred to the surrounding epidermal keratinocytes to protect
genomic DNA from ultraviolet light [1]. Overproduction and
accumulation of melanin pigment in the epidermis and/or dermis
causes cutaneous hyperpigmentation such as freckles, melasma,
senile lentigines and acquired bilateral dermal melanocytosis.
Thus, the inhibition ofmelanogenesis has been the focus ofmedical
treatment and cosmetics especially on the sun-exposed areas.
Melanogenesis is regulated by the key enzyme, tyrosinase, which is
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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).essential for the ﬁrst step of melanin biosynthesis, the conversion
of L-tyrosine to 3,4-dihydroxyphenylalanine (L-DOPA) and subse-
quent oxidation to dopaquinone [2]. Dopaquinone is a highly
reactive intermediate and gives rise to eumelanin production with
the participation of tyrosinase-related protein-1 (TYRP-1) and
TYRP-2 [3,4], while intervention of L-cysteine switches to
pheomelanin production [2,5]. Pheomelanin has been reported
to be cytotoxic due to the production of reactive oxygen species
(ROS) [6–8]. Thus, suppression of excess amounts of melanin and
suppression of intracellular ROS is necessary biochemical abilities
of safe and ideal skin-whitening agent.
More than ten kinds of skin-whitening compounds have been
produced and used as cosmetic ingredients. These quasi-drugs
prevent or improve hyperpigmentation by inhibiting tyrosinase
activity (ascorbic acid, kojic acid, arbutin and ellagic acid) or
decreasing tyrosinase protein (linoleic acid) [9]. They have been
used as cosmetic ingredients without causing the prominentociety for Investigative Dermatology. This is an open access article under the CC BY-
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TBP) is known to be the most potent phenolic derivative causing
occupational leukoderma [10–12] by inducing apoptosis in
melanocytes [13]. Monobenzyl ether of hydroquinone (MBEH) is
the only drug that the Food and Drug Administration has approved
for depigmentation therapy in the United States. Unlike 4-TBP,
MBEH induces necrotic cell death in melanocytes without
activating the caspase cascade or DNA fragmentation [14].
RS-4-(4-hydroxyphenyl)-2-butanol (rhododendrol or rhodode-
nol, RD) had been used since 2011 as a skin-whitening agent of
cosmetics produced and sold by Kanebo, a cosmetics company in
Tokyo, Japan. In July 2013, the cosmetics containing RD were
recalled by the company because approximately 2% of users
developed depigmentation on their face, neck and/or hands. The
Special Committee on the Safety of Cosmetics Containing
Rhododenol, established by the Japanese Dermatological Associa-
tion on July 17, 2013, labeled this cosmetics-associated depig-
mentation as RD-induced leukoderma [15]. Clinical characteristics
of RD-induced leukoderma show depigmentation of varying
severity that develops after the use of cosmetics mainly at the
site of use. Inmost cases repigmentation of a part or all the affected
areas is evident after discontinuation [15].
Until recently it was considered that depigmentation by RD-
containing cosmetics resulted from competitive inhibition of
tyrosinase by RD. However, approximately 20% of the patients
are still suffering from leukoderma on the face, neck and/or hands
without repigmentation. In addition, biopsied samples taken from
depigmented lesions of RD-induced leukoderma contain few or no
detectable epidermal melanocytes [15]. These clinicopathological
observations suggest that RD exhibits a signiﬁcant cytotoxicity to
the epidermal melanocytes by producing cytotoxic metabolites
through the tyrosinase-catalyzed oxidation. Tyrosinase is able to
oxidize, in addition to L-tyrosine, anumberof phenols and catechols
to form ortho-quinones [16]. Moreover, Sasaki et al. has reported
that RD mediates its cytotoxicity in a tyrosinase-dependent
manner, since suppression of tyrosinase results in the depressed
cytotoxicity of RD in melanocytes [17,18]. Recently we have[(Fig._1)TD$FIG]Fig. 1. RD suppressed growth of NHEMb and B16F1 cells but not that of NHEMa. Cells were
seven days.reported that RD was incorporated into the tyrosinase-dependent
biochemical pathway and produced RD-catechol and RD-cyclic
catechol in addition to the corresponding ortho-quinones
[19,20]. Moreover, RD-quinone was bound to non-protein thiols
and proteins in B16F1 cells through cysteinyl residues [21].
In order to elucidate further the molecular mechanism of
cytotoxicity of RD in melanocytic cells, we have analyzed the
effects of RD and its metabolic products RD-catechol and RD-cyclic
catechol on the growth of melanocytic cells and ROS production in
them. RD-catechol and RD-cyclic catechol showed cytotoxicity
much stronger than RD and RD-catechol as well as RD generated
ROS in B16F1 cells. The results obtained suggest that RD exerts its
cytotoxic effect through its metabolic products and that the ROS
production is related to RD-associated cytotoxicity.
2. Materials and methods
2.1. Cells and cultures
Normal human epidermal melanocytes (NHEMa, Asian/Cauca-
sian, newborn, Kurabo Cat KM-4009, Strain No. 00378) were
purchased from Kurabo Industries Ltd., Japan and cultured in the
medium DermaLife1 BM (LKB-LM0004) supplemented with
DermaLife1M LifeFactors (LMK-LS1041). Pigmented human epi-
dermal melanocytes derived from an African American female
(NHEMb, CC-2586, Lot 237204) were purchased from Lonza
Walkersville Inc. (MD) and cultured in the medium MBM-4
BulletKitTM supplemented with endothelin-3. Mouse melanoma
B16F1 cells were cultured in Dulbecco’s modiﬁed Eagle medium
supplemented by 10% fetal bovine serum and antibiotics.
2.2. Assay for cytotoxicity of phenolic compounds
To examine the cytotoxicity of phenolic compounds to NHEM
and B16F1 cells, cells were seeded at 1.5  105/6 cm dish and
cultured for 48 h. Cells were then refed with media containing
0–800mM RD and cultured for ﬁve or seven days. Numbers ofculturedwith RD (50–800 mM) and numbers of viable cells were counted for ﬁve or
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IC50 of the phenolic compounds, 2000 cells/well were seeded in
96-well plates, cultured for 24 h and then refed with the medium
containing RD, arbutin, hydroquinone or resveratrol for a further
72 h. Numbers of viable cells were counted by WST assay (Cell
Counting Kit-8, Dojindo, Wako Pure Chemical Industries Ltd.,
Japan).
2.3. Chemicals
Mushroom tyrosinase and arbutin (4-hydroquinone-D-gluco-
pyranoside) were purchased from Sigma–Aldrich (MO). L-Tyrosine,
hydroquinone (1,4-dihydroxybenzene) and resveratrol (3,5,40-
trihydroxy-trans-stilbene) were procured from Wako Pure Che-
micals Industries Ltd., Japan. Rhododendrol (RS-4-(4-Hydroxyphe-
nyl)-2-butanol, RD) was kindly provided by Innovative Beauty
Science Laboratory, Kanebo Cosmetics Inc., Japan.
2.4. Preparation of RD-catechol and RD-cyclic catechol
Initial preparation of these catechols on an mg scale was
reported in Ref. [19]. However, we needed them in greater
amounts and therefore made the following alterations to our
[(Fig._2)TD$FIG]
Fig. 2. RD exposure did not increase the subG1 fraction of NHEMb and B16F1 cells. Afte
collected and processed for ﬂow cytometric analysis. Population percentage of the submethods. For the rhododendrol-catechol, a solution of rhododen-
drol (166 mg, 1.0 mmol, dissolved in 1 mL ethanol), ascorbic acid
(1056 mg, 6 mmol), and Na2HPO4 (852 mg, 6 mmol) was prepared
with 100 mL 50 mM sodium phosphate buffer (pH 5.3). The
resulting pH was 5.3. The mixture was vigorously shaken at 37 8C
upon which mushroom tyrosinase (58 mg; 100,000 U) in 2 mL
buffer was added. After 60 min, HPLC analysis showed that most of
the ascorbic acid was consumed while 7% of the substrate
rhododendrol remained. Thus, the oxidation was stopped by
adding 400 mg NaBH4 and then 20 mL 1 M HCl. The mixture was
extracted with ethyl acetate (200 mL and 100 mL), and the organic
layers were combined, washed once with 40 mL saturated NaCl
solution, dried over anhydrous Na2SO4 and evaporated to dryness
under reduced pressure. The residue was dissolved in 2 mL DMSO
and subjected to preparative HPLC (see below) to afford, after
evaporation, 138 mg (80% yield) of rhododendrol-catechol as
colorless oil (HPLC purity > 99%).
For the rhododendrol-catechol, a solution of rhododendrol
(166 mg, 1.0 mmol, dissolved in 1 mL ethanol) was prepared with
100 mL 50 mMsodiumphosphate buffer (pH 5.3). Themixturewas
vigorously shaken at 37 8C upon which mushroom tyrosinase
(58 mg; 100,000 U) in 2 mL buffer was added. After 20 min, HPLC
analysis showed that most (95%) of the substrate rhododendrolr NHEMb and B16F1 cells were cultured with RD, adherent and ﬂoating cells were
G1 phase is quantiﬁed and shown in the ﬁgures.
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NaBH4 and then 20 mL 1 M HCl. The mixture was extracted with
ethyl acetate (200 mL and 100 mL), and the organic layers were
combined, washed once with a 40 mL saturated NaCl solution,
dried over anhydrous Na2SO4 and evaporated to dryness under
reduced pressure. The residue was dissolved in 2 mL DMSO and
subjected to preparative HPLC (see below) to afford, after
evaporation, 32 mg (18% yield) of rhododendrol-cyclic catechol
as pale yellow oil (HPLC purity 97%).
Preparative HPLC was performed as follows. An HPLC system
consisted of a JASCO PU-2080 Plus pump (JASCO Co., Tokyo, Japan),
a Shiseido C18 column (Capcell Pak MG; 20  250 mm; 5mm
particle size, Shiseido, Tokyo, Japan) and a JASCO UV/visible
detector at 280 nm (JASCO Co., Tokyo, Japan). The mobile phase
was 0.4 M formic acid:methanol, 60:40 (v/v) at 40 8C at a ﬂow rate
of 7.0 mL/min. RD, RD-catechol, and RD-cyclic catechol were
dissolved at 100 mM concentrations in ethanol and stored at
80 8C until use.
2.5. Measurement of ROS
After cells were cultured in the medium containing 5 mM CM-
H2DCFDA (DCF, Invitrogen) for 30 min at 37 8C, they were washed
with PBS, refed with the medium containing RD, RD-catechol or
RD-cyclic catechol and cultured for a further 24 h. Adherent and
ﬂoating cells were then combined and washed with PBS twice. The
cells were suspended in 600 ml PBS and processed for ﬂow
cytometry to quantify the FITC-H (Becton Dickinson, CA, USA)
[(Fig._3)TD$FIG]Fig. 3. RD produced ROS in NHEMb and B16F1 cells. (a) As a positive control, B16F1 cells
500mM) for 24 h. (b, c) After B16F1 (b) and NHEMb (c) cells were treated with DCF for 3
described in Section 2.using the Cell QUEST program. For the positive control, the cells
were cultured with H2O2 (100 or 500 mM) for 24 h. Adherent and
ﬂoating cells were then collected and processed as described
above. We also detected intracellular ROS using a confocal
ﬂuorescence microscope (ZEISS/confoCor3LSM510META). For this,
3  104 B16F1 cells were separately seeded on round glass
coverslips that were coated with Atelo Cell IPC-30 (KOKEN, Tokyo)
and put into each well of 12-well plates. After cells were cultured
for 24 h, they were stained with 5 mM CM-H2DCFDA for 30 min.
They were then cultured in the medium containing RD (500mM).
After being cultured for 24 h, they were incubated at room
temperature in 4% paraformaldehyde containingHoechst33342 for
15 min. By these methods, intracellular ROS and cellular nuclei
were stained to green and blue, respectively.
2.6. Flow cytometric analysis
Cells were cultured in the medium containing RD, RD-catechol
or RD-cyclic catechol for 48 h and processed as described
previously [22]. The adherent and ﬂoating cells were combined,
washed in PBS, dehydrated in 70% cold ethanol and stored on ice
for 2 h. Theywere then rehydrated in cold PBS and incubated in the
presence of RNase A (100 mg/ml) (Invitrogen, CA) at 37 8C for
30 min. After incubation, the cells were rinsed twice in cold PBS
and suspended in 800ml of PBS containing 50 mg/ml propidium
iodide (Wako) at 4 8C for 2 h. SubG1, G1, S, and G2/M populations
were quantiﬁed with a FACSCalibur ﬂow cytometer (Becton
Dickinson, CA) using the Cell QUEST program.were treated with DCF for 30 min and then cultured in the presence of H2O2 (100 or
0 min, cells were cultured with RD for 24 h. ROS was detected by ﬂow cytometry as
[2_TD$DIFF] able 1
IC50 of phenol derivatives in cultured cell.
IC50 (mM)a
B16F1 NHEMb
RD 670.8 1052.5
Arbutin 41,200 12,200
Hydroquinone 28.3 9.4
Resveratrol 27.1 38.2
a IC50 is the concentration of each phenolic compounds that suppressed cell
growth to 50% after cells were cultured with drugs for 72h.
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Mean standard error (n = 8) and statistical signiﬁcance of data
were analyzed by the Student’s t-test.
3. Results
3.1. RD suppressed growth of pigmented human melanocytes and
B16F1 cells
First, we examined the effect of RD on the growth of normal
human epidermal melanocytes (NHEMa and NHEMb) and mouse
B16F1melanoma cells. RD did not affect the growth of NHEMa cells
derived from Asian/Caucasian newborns that contained only small
amounts of melanin pigments. However, RD suppressed the
growth of pigmented NHEMb and B16F1 cells at the concentration
of 500mM and 200 mM, respectively (Fig. 1). To compare the
cytotoxicity of RD with other phenolic compounds, we examined
the growth of the melanocytic cells in the presence of arbutin,
hydroquinone or resveratrol and determined their IC50. As shown
in Table 1, IC50 of RD in B16F1 (671mM) and NHEMb cells
(1053 mM) was signiﬁcantly higher than resveratrol (27.1 and
38.2 mM) and hydroquinone (28.3 and 9.4 mM), but much lower
than arbutin (41,200 and 12,200mM). This suggests that RD-
mediated cytotoxicity was relatively moderate compared to
hydroquinone and resveratrol, and arbutin has little cytotoxicity
to melanocytic cells.
To analyze the molecular mechanism of growth suppression of
melanocytic cells, ﬂow cytometric analysis was performed using
cells cultured for two days in the presence of RD. The NHEMb and
B16F1 cellswere culturedwith 300 or 500 mMRDor 500mMH2O2,
concentrations at which almost all the cells were degraded. As
shown in Fig. 2, ﬂow cytometry did not detect the increase of the[(Fig._4)TD$FIG]Fig. 4. RD-catechol and RD-cyclic catechol suppressed growth of B16F1 cells more signiﬁc
RD, RD-catechol or RD-cyclic catechol for 24 h and numbers of cells were counted bysubG1 fraction (Fig. 2a–c). Instead, the results showed a remark-
able increase in the S throughG2/Mphase, suggesting the cell cycle
was arrested halfway through the process of DNA replication.
Activated caspase 3 was not observed in the cells exposed to RD
(data not shown). These results suggest that the major mechanism
of growth suppression by RD did not occur through the process of
apoptotic cell death but through the cell cycle arrest and cell
degradation.
3.2. RD produces ROS in melanocytic cells
Flow cytometry was used to measure the levels of intracellular
ROS through the use of cells ﬁrst treated with DCF and then
cultured with RD as described in Section 2. When NHEMb and
B16F1 cells were exposed to DCF and RD, they produced ROS, the
quantity of which was clearly detected by ﬂow cytometry (Fig. 3).
The quantity of ROS in the NHEMb exposed to 300 mM RD was
larger than that of B16F1 cells exposed to 300 mM RD or 500 mM
H2O2, suggesting that epidermis-derived melanocytes are
more susceptible to ROS production by RD (Fig. 3a–c). We also
detected ROS by confocal microscopy in the B16F1 and NHEMb
cells after they were cultured in the RD-containing mediaantly than RD. B16F1 (a–c), NHEMb (d–f) and NHEMa (g–i) cells were cultured with
WST assay. *p < 0.05, **p < 0.0001 versus untreated control.
[(Fig._5)TD$FIG]
Fig. 5. ROS production and cell cycle of B16F1 cells exposed to RD-catalytic metabolites. ROS production of B16F1 cells exposed to RD-catechol (a), cell cycle analysis of B16F1
cells exposed to RD-catechol (b), ROS production of B16F1 cells exposed to RD-cyclic catechol (c) and cell cycle analysis of B16F1 cells exposed to RD-cyclic catechol (d) were
analyzed by ﬂow cytometry as described in Section 2.
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detected in the RD-treated cells, apoptotic cell death was not
observed in these melanocytic cells as described above. This
suggests, therefore, that ROS production did not result in the cell
degradation by the process of apoptotic cell death.
Supplementary Fig. 1 related to this article can be found, in the
online version, at http://dx.doi.org/10.1016/j.jdermsci.2015.07.010.
3.3. RD-metabolites suppressed growth of B16F1 more signiﬁcantly
than RD
The major products of tyrosinase-catalyzed RD oxidation were
RD-catechol and RD-cyclic catechol [19]. We analyzed their
inhibitory effects on the growth of B16F1 cells and production
of ROS. After B16F1 cell were cultured with RD, RD-catechol or RD-
cyclic catechol for 24 h, the number of cells was counted by WST
assay. Survival cells were reduced in the RD-catechol- or RD-cyclic
catechol-treated cells more signiﬁcantly in than RD-treated cells
(Fig. 4a–i). The number of survival cells was remarkably reduced in
the NHEMa and NHEMb cells compared to B16F1 cells in the
medium containing RD-catechol or RD-cyclic catechol at a
concentration of greater than 50 or 20 mM, respectively (Fig. 4e,
f, h and i).
Because B16F1 cells cultured for 48 h in the presence of
>100mM RD-catechol or >30 [4_TD$DIFF]mM RD-cyclic catechol severely
degraded, ﬂow cytometric analysis was performed in the mediacontaining 100 mM RD-catechol or 30 mM RD-cyclic catechol
(Fig. 5). Results indicated that RD-catechol produced a signiﬁcant
amount of ROS in B16F1 cells, while RD-cyclic catechol did not
produce a detectable amount of ROS (Fig. 5a and c). Immunocyto-
chemistry also detected ROS production in the RD- and RD-
catechol-treated B16F1 cells (Fig. 6). However, RD-cyclic catechol
produced only a small amount of ROS in accordance to ﬂow
cytometric analysis. Differing from RD-treated cells, RD-catechol-
and RD-cyclic catechol-treated cells showed a slightly increased
subG1 fraction (Fig. 5b and d). These results suggest that RD-
mediated cytotoxicity depends on the RD-catalyzed metabolites,
RD-catechol and RD-cyclic catechol, but ROS production is not
required for degradation of melanocytic cells by RD-cyclic catechol.
4. Discussion
Occupational leukoderma was reported on hands and ﬁngers
among the workers of Japanese raspberry factory preparing 4-(4-
hydroxyphenyl)-2-butanone, the structure of which is very similar
to RD [23]. The biochemical characterization of RD was ﬁrst
described by Akazawa et al. [24] as a phenolic compound, isolated
from the bark of Acer nikoense, which displayed tyrosinase
inhibition and cytotoxicity to B16F1 cells. However, it had not
been known that RD-containing cosmetics could induce leuko-
derma on the sites of application until the Kanebo’s July 4,
2013 press release.
[(Fig._6)TD$FIG]
Fig. 6. The ﬂuorescence microphotographs of ROS in B16F1 cells treated with RD and its metabolites. The cells were treated with RD, RD-catechol or RD-cyclic catechol and
stained with CM-H2DCFDA and Hochst33342 that reacted with ROS (green [3_TD$DIFF], observed in the DCFDA+RD and DCFDA+RD-catechol cells) and the nuclei of the cells (blue),
respectively. Scale bar 10mm[1_TD$DIFF].
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activity of cellular tyrosinase prepared from melanocytes exposed
to RD [17,18]. According to our mushroom tyrosinase assay, the
inhibitory activity of tyrosinase by RD (IC50: 89.7mM) was
comparable to hydroquinone (IC50: 94.6mM) but weaker than
resveratrol (IC50: 23.0mM) (data not shown). The growth
inhibition assay showed that the proliferation of pigmented
human melanocytes (NHEMb) and B16F1 cells was clearly
suppressed by RD, while that of low-pigmented human melano-
cytes (NHEMa) was not. This was consistent with other previous
results [17,18]. Among the phenolic compounds tested, the
cytotoxicity of RD to NHEMb and B16F1 cells was milder than
hydroquinone and resveratrol. Consequently, it is difﬁcult to
distinguish leukoderma-inducible compounds from non-inducible
ones by the combination of tyrosinase assay and growth inhibition
assay.
To elucidate further the molecular mechanism of cytotoxicity
by RD, we have analyzed RD-treated cells by ﬂow cytometry.
Although both the NHEMb and B16F1 cells generated ROS when
they were exposed to RD for 48 h, their subG1 fractions were not
clearly increased and activated caspase 3 could not be detected.
Interestingly, the frequency of S and G2/M phase cells increased
signiﬁcantly in the RD-treated B16F1 but not signiﬁcantly in the
NHEMb cells. The difference in the S and G2/M phases between the
two cells is not clear, but it might be related to the duration of the
cell cycle between two cells. These results suggest that cytotoxicity
of RD to melanocytic cells results from cell cycle arrest that can
induce degradation of cells without apoptosis. Yang et al. [25]
reported that in melanocytic cells treated with 300–900 mM RD,autophagosome makers LC3II and LAMP1 were markedly upre-
gulated. The phenolic substances are good substrates for
tyrosinase and produce reactive ortho-quinones that can bind
to cellular thiol compounds such as cysteine and GSH through the
sulfhydryl group [26–28].We have also reported that RD-quinone
and RD-cyclic quinone reacted rapidly with cellular thiols
[19]. Moreover, we examined the metabolism of RD in B16F1
cells and conﬁrmed the production of RD-pheomelanin and
covalent binding of RD-quinone to cellular proteins [21]. Thus, it
can be surmised that the interaction of RD-oxidative compounds
with the cellular sulfhydryl group resulted in the cell cycle arrest
and autophagy.
We have previously reported that a phenolic compound, N-
propionyl-4-S-cysteaminylphenol (NPr-4-S-CAP) was selectively
incorporated into themelanin biosynthesis cascade of melanocytic
cells and induced apoptotic cell death through ROS production
[22,29]. Recently, we have shown that RD is also incorporated into
the tyrosinase-initiated biochemical pathway to produce oxidative
metabolites [19,20]. It can therefore be estimated that tyrosinase-
catalyzed products, RD-catechol and RD-cyclic catechol, exert
cytotoxicity more strongly than RD. In the present study, we have
shown that RD-catechol and RD-cyclic catechol possessed
cytotoxicity in B16F1, NHEMa and NHEMb cells more strongly
than RD. In particular, growth of NHEMa and NHEMb was
completely suppressed by a concentration of RD metabolites as
low as 100 mM (Supplementary Fig. 2), indicating RD-catechol and
RD-cyclic catechol is >10 fold more cytotoxic to NHEM cells.
Supplementary Fig. 2 related to this article can be found, in the
online version, at http://dx.doi.org/10.1016/j.jdermsci.2015.07.010.
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showed increased amounts of the subG1 fraction. Further analyses
are required to elucidate why these two metabolites showed
different biochemical activities. The results obtained suggest that
RD-oxidized metabolites and ROS production are at least partially
responsible for cell degradation. Catechols are known to be
cytotoxic through the production of ROS and/or the ortho-
quinones, depending on their structure [30]. In the present study
it was not examinedwhether the RD-derived ortho-quninones, RD-
quinone and RD-cyclic quinone, are involved in the cytotoxicity of
RD. Our recent study using B16F1 cells exposed to RD, RD-quinone
thio-ether adductswere detected,while RD-catechol and RD-cyclic
catechol were not detected at appreciable levels [21]. This may
suggest that these catechols are rapidly oxidized in melanocytes,
producing ROS [19]. The recent studies suggest that RD-mediated
degradation of epidermal melanocytes induces host immunity
involving CCR4+CCR8+ T cells [31,32]. It remains unclearwhether a
part of RD and/or RD metabolites or a related peptide could be
presented on the MHC class 1 molecule to mediate host cell
immunity.
Both NPr-4-S-CAP and RD have been shown to be oxidized by
tyrosinase [19,20,28,33] and exert cytotoxicity to melanocytic
cells. We suggest that, in addition to the assay for tyrosinase
inhibition and B16F1 cell cytotoxicity, the phenolic or catechol
compounds should be tested for their potential to be incorporated
into themelanin biosynthetic pathway as a substrate of tyrosinase.
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